The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.

Regulation of the activity of the proinflammatory cytokine IL-1 is complex, involving transcriptional and translational control, precursor processing, a receptor antagonist (IL-1ra), and a decoy receptor. Here we report that the soluble form of the IL-1 receptor accessory protein (AcP) increases the affinity of binding of human IL-1alpha and IL-1beta to the soluble human type II IL-1 receptor by approximately 100-fold, while leaving unaltered the low binding affinity of IL-1ra. Soluble AcP is present in normal human serum at an average concentration greater than 300 ng/ml. These findings suggest that the soluble form of IL-1R AcP contributes to the antagonism of IL-1 action by the type II decoy receptor, adding another layer of complexity to the regulation of IL-1 action.

[1]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[2]  A. Whitehead,et al.  IL-1 Signaling Cascade in Liver Cells and the Involvement of a Soluble Form of the IL-1 Receptor Accessory Protein1 2 , 2000, The Journal of Immunology.

[3]  A. H. Drummond,et al.  Role of Metalloproteases in the Release of the IL-1 type II Decoy Receptor* , 1997, The Journal of Biological Chemistry.

[4]  F. Villinger,et al.  Comparative sequence analysis of cytokine genes from human and nonhuman primates. , 1995, Journal of immunology.

[5]  M. Seldin,et al.  Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34. , 1994, The EMBO journal.

[6]  J. Dayer,et al.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. , 1995, The Journal of clinical investigation.

[7]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[8]  A. Aruffo,et al.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.

[9]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[10]  C. Dinarello,et al.  Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. , 1998, International reviews of immunology.

[11]  J. Symons,et al.  CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS , 1988, The Lancet.

[12]  T. Bártfai,et al.  Interleukin‐1 receptor accessory protein interacts with the type II interleukin‐1 receptor , 1998, FEBS letters.

[13]  J. Derry,et al.  Inflammation and Inflammatory Bowel Disease , 2022 .

[14]  T. Sata,et al.  Molecular Cloning and Expression of Cynomolgus Monkey Interferon-γ cDNA , 1997 .

[15]  M. Piazza,et al.  HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE , 1975, The Lancet.

[16]  Dirk E. Smith,et al.  A Single Amino Acid Difference between Human and Monkey Interleukin (IL)-1β Dictates Effective Binding to Soluble Type II IL-1 Receptor* , 2002, The Journal of Biological Chemistry.

[17]  K. Huebner,et al.  A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.

[18]  S. Dower,et al.  Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.

[19]  J. Dayer,et al.  Anti–interleukin-1 therapy in rheumatic diseases , 2001, Current opinion in rheumatology.

[20]  M Locati,et al.  Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. , 2001, Trends in immunology.

[21]  M. Labow,et al.  Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex (*) , 1995, The Journal of Biological Chemistry.

[22]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[23]  D. Boraschi,et al.  The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. , 1998, Journal of immunology.

[24]  C. Dinarello,et al.  Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. , 1998, Arthritis and rheumatism.

[25]  B. Castner,et al.  Further evidence for a common mechanism for shedding of cell surface proteins , 1997, FEBS letters.